SYNAGEVA BIOPHARMA CORP - FORM 10-K - EX-23.1 - CONSENT OF ERNST AND YOUNG LLP - March 16, 2010

Attached files

file filename
EX-31.1 - CERTIFICATION BY MARTIN A. MATTINGLY AS CEO - SYNAGEVA BIOPHARMA CORPdex311.htm
EX-23.2 - CONSENT OF KPMG LLP - SYNAGEVA BIOPHARMA CORPdex232.htm
EX-32.2 - SECTION 1350 CERTIFICATION BY ANDREW L. GRAHAM AS CFO - SYNAGEVA BIOPHARMA CORPdex322.htm
EX-31.2 - CERTIFICATION BY ANDREW L. GRAHAM AS CFO - SYNAGEVA BIOPHARMA CORPdex312.htm
EX-32.1 - SECTION 1350 CERTIFICATION BY MARTIN A. MATTINGLY AS CEO - SYNAGEVA BIOPHARMA CORPdex321.htm
10-K - FORM 10-K - SYNAGEVA BIOPHARMA CORPd10k.htm

Exhibit 23.1

 

Consent of Independent Registered Public Accounting Firm

 

We consent to the incorporation by reference in the Registration Statements (Form S-8 Nos. 333-44145, 333-64064, 333-66401, 333-74304, 333-90377, 333-107508, 333-129600, 333-138807, 333-147430 and 333-147431) of Trimeris, Inc. of our reports dated March 16, 2010, with respect to the financial statements of Trimeris, Inc., and the effectiveness of internal control over financial reporting of Trimeris, Inc., included in this Annual Report (Form 10-K) for the year ended December 31, 2009.

 

/s/ Ernst & Young LLP

 

Raleigh, North Carolina

March 16, 2010

Stock widget

Investing forum

SYNAGEVA BIOPHARMA CORP Reports